Sugi Predict

Sugi Predict / Compounds / SCHEMBL16637001

SCHEMBL16637001

SCHEMBL16637001

CC(C)(C)OC(=O)N1CCN(c2nc(Cl)nc3c(F)c(Br)c(Cl)cc23)CC1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KCNH2 Q12809 2/20 0.42
▸ TLR9 Q9NR96 1/20 0.42
▸ GBA1 P04062 2/20 0.41
▸ CNR1 P21554 1/20 0.40
▸ CNR2 P34972 1/20 0.40
▸ SUV39H2 Q9H5I1 4/20 0.40
▸ KIT P10721 1/20 0.39
▸ GRIA1 P42261 1/20 0.39
▸ CXCR2 P25025 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ BACE1 P56817 2/20 0.38
▸ NR1H2 P55055 1/20 0.38
▸ NR1H3 Q13133 1/20 0.38
▸ MAP4K4 O95819 1/20 0.38
▸ MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29409403 1.00 KCNH2 (0.42) KCNH2TLR9GBA1CNR1CNR2
SCHEMBL30015244 0.94 KCNH2 (0.41) KCNH2TLR9GBA1CNR1CNR2
SCHEMBL24161673 0.92 GBA1 (0.43) KCNH2TLR9GBA1CNR1CNR2
SCHEMBL25339096 0.92 KCNH2 (0.42) KCNH2TLR9GBA1CNR1CNR2
SCHEMBL29914108 0.92 GBA1 (0.43) KCNH2TLR9GBA1CNR1CNR2
SCHEMBL31169895 0.90 KCNH2 (0.41) KCNH2TLR9GBA1CNR1CNR2
SCHEMBL25920297 0.90 KCNH2 (0.37) KCNH2TLR9GBA1CNR1CNR2
SCHEMBL24917972 0.89 KCNH2 (0.42) KCNH2TLR9GBA1CNR1CNR2
SCHEMBL26967343 0.89 TLR9 (0.51) KCNH2TLR9GBA1SUV39H2
SCHEMBL24717244 0.89 CXCR2 (0.42) KCNH2TLR9GBA1CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630547-B2 RAS protein degraders, pharmaceutical compositions thereof, and their therapeutic applications BIOTHERYX, INC. (US) 2026-05-19 — — US disclosed
US-12552783-B2 Modulators of proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2026-02-17 — — US disclosed
US-20250263424-A1 KRAS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2025-08-21 — — US disclosed
US-12365676-B2 Heterocyclic compounds and uses thereof KUMQUAT BIOSCIENCES INC. (US) 2025-07-22 — — US disclosed
US-RE50490-E1 Substituted quinazoline compounds and methods of use thereof ARAXES PHARMA LLC (US) 2025-07-15 — — US disclosed
EP-4568952-A1 KRAS INHIBITORS Bristol-Myers Squibb Company (US) 2025-06-18 — — EP disclosed
US-12286427-B2 Heterocyclic compounds and uses thereof KUMQUAT BIOSCIENCES INC. (US) 2025-04-29 — — US disclosed
EP-4305037-B1 KRAS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2025-02-26 — — EP disclosed
US-12234244-B2 Substituted piperazines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2025-02-25 — — US disclosed
US-20250059179-A1 Heterocyclic Compounds and Methods of Use AMGEN INC. (US) 2025-02-20 — — US disclosed
US-20160297774-A1 SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF ARAXES PHARMA LLC 2016-10-13 — — US disclosed
WO-2016164675-A1 SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF ARAXES PHARMA LLC (US) 2016-10-13 — — WO disclosed
WO-2016164675-A1 SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF ARAXES PHARMA LLC (US) 2016-10-13 — — WO disclosed
US-20160297774-A1 SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF ARAXES PHARMA LLC 2016-10-13 — — US disclosed
EP-3055290-A1 INHIBITORS OF KRAS G12C Araxes Pharma LLC (US) 2016-08-17 — — EP disclosed
US-20150239900-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2015-08-27 — — US disclosed
US-20150239900-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2015-08-27 — — US disclosed
US-20150239900-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2015-08-27 — — US disclosed
WO-2015054572-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2015-04-16 — — WO disclosed
WO-2015054572-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2015-04-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630547-B2 RAS protein degraders, pharmaceutical compositions thereof, and their therapeutic applications KRAS, RSU1, NRAS KCNH2 4671/4885TLR9 4848/4885GBA1 1640/4885
US-12234244-B2 Substituted piperazines as inhibitors of KRAS G12C KRAS, NRAS, HRAS KCNH2 2775/4885TLR9 3734/4885GBA1 1981/4885
US-12286427-B2 Heterocyclic compounds and uses thereof TP53, KRAS, HRAS KCNH2 4621/4885TLR9 4339/4885GBA1 2041/4885
US-12365676-B2 Heterocyclic compounds and uses thereof TP53, KRAS, HRAS KCNH2 4621/4885TLR9 4339/4885GBA1 2041/4885
US-20250059179-A1 Heterocyclic Compounds and Methods of Use KRAS, NRAS, HRAS KCNH2 4375/4885TLR9 4400/4885GBA1 1539/4885
US-20160297774-A1 SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF KRAS, NRAS, HRAS KCNH2 3801/4885TLR9 4089/4885GBA1 1251/4885
US-20150239900-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS KCNH2 4508/4885TLR9 3879/4885GBA1 1100/4885
US-20250263424-A1 KRAS INHIBITORS KRAS, NRAS, HRAS KCNH2 4689/4885TLR9 4405/4885GBA1 3034/4885
US-12552783-B2 Modulators of proteolysis and associated methods of use CRBN, ADRM1, MDM2 KCNH2 4731/4885TLR9 4697/4885GBA1 2969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.